Multieffect Specific Nanovesicles for Homing Resistant Tumors and Overcoming Osimertinib‐Acquired Resistance in NSCLC
Advanced Healthcare Materials · 2025-04 · 14 (9)
DOI: 10.1002/adhm.202404087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 18.02.2025. Verfasst von Yuanyao Dou und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, 400042, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms, Acrylamides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 79 Literaturangaben. Gefördert von: Talent Cultivation Project of Army Medical University, National Natural Science Foundation of China, Chongqing Technology Innovation and Application Development Special Key Project.
Abstract (Originalsprache)
Acquired resistance to osimertinib (Osi) remains a major obstacle in the treatment of patients with EGFR‐mutant non‐small cell lung cancer (NSCLC). AXL elevation is a known key mechanism of Osi‐resistance, and therapeutic strategies remain scarce. Emerging evidence reveals that an increased intracellular glutathione (GSH) level induces Osi resistance. In this study, a new mechanism is identified by which GSH regulates AXL expression via glutathione peroxidase 4 (GPX4) in Osi‐resistant cells. A multifunctional covalent organic framework (COF) nanoplatform for GSH consumption, AXL inhibition, and co‐delivery of the AXL inhibitor (Brigatinib) and Osi is creatively constructed to confirm whether Osi sensitivity improves by simultaneously targeting GSH‐AXL resistance mechanisms. Furthermore, it is coated, for the first time, the COF carrier system with specific vesicles to precisely home it into resistant tumors, where CDH2 adhesion molecules play a crucial role. The engineered multifunctional antiresistance‐specific nanovesicles effectively inhibited the GSH‐AXL axis, induced apoptosis in Osi‐resistant cells both in vitro and in vivo, and delayed the progression of Osi‐resistant tumors. Overall, these findings provide a novel strategy to overcome the Osi‐acquired resistance caused by high AXL levels in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, 400042, China.
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400044, China.
- Department of Respiratory Disease, Bishan hospital of Chongqing Medical University, Bishan Hospital of Chongqing, Chongqing, 402760, China.
- School of Medicine, Chongqing University, Chongqing, 400044, China.
- Department of pain treatment, The seventh people's Hospital of Chongqing, Chongqing, 401320, China.
ORCID-Profile: Liling Tang, Yong He
Förderung
- Talent Cultivation Project of Army Medical University
- National Natural Science Foundation of China
- Chongqing Technology Innovation and Application Development Special Key Project
- National Science and Technology Major Project
Zitieren
APA
Dou, Y., Liu, Y., Han, R., Zheng, J., Wang, L., Hu, C., Huang, D., He, C., Zhang, Y., Lin, C., Lu, C., Wu, D., Tang, H., He, T., Tang, L., & He, Y. (2025). Multieffect Specific Nanovesicles for Homing Resistant Tumors and Overcoming Osimertinib‐Acquired Resistance in NSCLC. Advanced Healthcare Materials, 14(9). https://doi.org/10.1002/adhm.202404087
Vancouver
Dou Y, Liu Y, Han R, Zheng J, Wang L, Hu C, et al. Multieffect Specific Nanovesicles for Homing Resistant Tumors and Overcoming Osimertinib‐Acquired Resistance in NSCLC. Advanced Healthcare Materials. 2025;14(9). doi:10.1002/adhm.202404087
BibTeX
@article{Dou2025,
author = {Dou, Yuanyao and Liu, Yihui and Han, Rui and Zheng, Jie and Wang, Liping and Hu, Chen and Huang, Daijuan and He, Chao and Zhang, Yimin and Lin, Caiyu and Lu, Conghua and Wu, Di and Tang, Huan and He, Tingting and Tang, Liling and He, Yong},
title = {Multieffect Specific Nanovesicles for Homing Resistant Tumors and Overcoming Osimertinib‐Acquired Resistance in NSCLC},
journal = {Advanced Healthcare Materials},
year = {2025},
volume = {14},
number = {9},
doi = {10.1002/adhm.202404087}
}
EUVIMED